7th CKD3 Summit 2025
The 7th CKD Drug Development Summit returns in 2025 as the definitive forum for connecting industry leaders, KOLs, researchers, and regulators. Addressing the most pressing challenges across renal research and development, this event serves as the unrivaled platform to share breakthroughs, inspire collaboration, and advance strategies for improving clinical outcomes in renal care all to bring better drugs to patients faster.
Returning for its 7th year, the Chronic Kidney Disease Drug Development Summit (CKD3) is the definitive forum for advancing innovation in kidney health, uniting over 180 global experts spanning discovery, preclinical, translational, clinical, and regulatory fields.
As the CKD landscape celebrates major milestones like Novartis` Borealis Biosciences launch, IgAN approval, and transformative acquisitions by Biogen, Vertex, and Apellis, the field stands at the forefront of a Kidney Renaissance. With the FDA’s increasing support for accelerated approval pathways and a surge of new therapies targeting both rare and common kidney diseases, the CKD3 Summit provides a pivotal opportunity to shape the future of renal drug development.
Discover Breakthrough Therapies
Dive into how game-changing advancements like SGLT2i, GLP-1s, and MRAs are reshaping CKD care with insights from AstraZeneca, Sanofi, Bayer, and Eli Lilly. Understand their impact on drug discovery, development, and clinical trial design to keep pace with the evolving treatment paradigm.
Advance Precision Medicine in CKD
Hear from leaders like Matthias Kretzler and Bayer as they explore cutting-edge strategies for translating genetic and molecular insights into clinical practice, tailoring treatments to diverse CKD subpopulations, and advancing personalized care.
Unlock Opportunities in Glomerular Diseases
Join Jonathan Barratt, Calliditas, and Travere Therapeutics to examine breakthroughs in glomerular diseases beyond IgA nephropathy, addressing FSGS, lupus nephritis, C3G, and membranous nephropathy, and identify paths to improve patient outcomes.
Dive Into Next-Generation CKD Workshops
Engage in discussion-based workshops tackling the biggest challenges in CKD drug development, from leveraging omics and real-world data for target discovery to advancing pediatric nephrology and mastering hierarchical composite endpoints with Alexion, Boehringer Ingelheim, and more.
Join us in March 2025 in Boston to shape the future of kidney care in the transformative era of renal drug development!
What You Can Expect:
- 180+ Global Attendees from Across the Renal Landscape
- 40+ Expert Speakers with Unique Insights
- 10+ Hours of Face-to-Face Networking Opportunities
- 3 Days of Unmissable Data-Driven Content
- 2 Dedicate Tracks of Content for the Whole Team
- 1 Brand-New Focus Day Dedicated to Glomerular Disease
- 3 Unmissable Deep Dive Workshops with Industry Leaders
Advance More Personalized Therapies for Rare & Common Kidney Diseases
The transformative era of kidney drug development is here, with 2024 bringing landmark advancements, including Novartis’ Borealis Biosciences and approvals in IgAN, Travere Therapeutics, and industry-defining acquisitions by Biogen and Vertex. Breakthrough therapies like SGLT2 inhibitors, GLP-1s, and MRAs continue to reshape the CKD treatment paradigm, while the FDA’s accelerated pathways fuel unprecedented innovation. We are witnessing a renaissance in chronic kidney disease research and development and treatment.
The 7th CKD Drug Development Summit returns in 2025 as the definitive forum for connecting industry leaders, KOLs, researchers, and regulators. Addressing the most pressing challenges across renal research and development, this event serves as the unrivaled platform to share breakthroughs, inspire collaboration, and advance strategies for improving clinical outcomes in renal care all to bring better drugs to patients faster.
The flagship summit returns for its 7th iteration with an end-to-end program full of unrivaled scientific content across two tracks, perfect for all your teams:
- Track 1: Discovery, Preclinical & Translational
- Track 2: Clinical Innovation, Regulatory & Outcomes Track
This summit showcases groundbreaking research into novel targets, pipeline breakthroughs, and real-world patient studies with exclusive insights from the FDA, Apellis Pharmaceuticals, NephCure Kidney International, Travere Therapeutics, and more.
Deep dive into three discussion-based workshops from translating omics data and RWE into meaningful insights for development, advancing pediatric nephrology, and mastering hierarchical composite endpoints to supercharge the next generation of therapeutics with Alexion, Purespring, and Boehringer Ingelheim.
Showcase your groundbreaking research, understand what your peers are working on, and discover the latest innovations in CKD.
Network and forge valuable connections and reconnect with industry leaders through drinks receptions, speed networking sessions, lunch briefings, and more. You could have Joined over 150+ CKD experts from various sectors within the biopharma landscape.
Hear cutting-edge pipeline updates, promising pediatric trial data, and regulatory insights on the evolving landscape of acceptable surrogate endpoints.
